创新融资工具在全球卫生领域的应用：2002-2015 年系统性分析。
Innovative financing instruments for global health 2002-15: a systematic analysis.
机构信息
Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA.
Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA.
出版信息
Lancet Glob Health. 2017 Jul;5(7):e720-e726. doi: 10.1016/S2214-109X(17)30198-5.
Development assistance for health (DAH), the value of which peaked in 2013 and fell in 2015, is unlikely to rise substantially in the near future, increasing reliance on domestic and innovative financing sources to sustain health programmes in low-income and middle-income countries. We examined innovative financing instruments (IFIs)-financing schemes that generate and mobilise funds-to estimate the quantum of financing mobilised from 2002 to 2015. We identified ten IFIs, which mobilised US$8·9 billion (2·3% of overall DAH) in 2002-15. The funds generated by IFIs were channelled mostly through GAVI and the Global Fund, and used for programmes for new and underused vaccines, HIV/AIDS, malaria, tuberculosis, and maternal and child health. Vaccination programmes received the largest amount of funding ($2·6 billion), followed by HIV/AIDS ($1080·7 million) and malaria ($1028·9 million), with no discernible funding targeted to non-communicable diseases.
卫生发展援助（DAH）的价值在 2013 年达到峰值，2015 年下降，在不久的将来不太可能大幅增加，这增加了对国内和创新融资来源的依赖，以维持低收入和中等收入国家的卫生计划。我们研究了创新融资工具（IFIs）-产生和调动资金的融资计划-以估计 2002 年至 2015 年动员的资金数量。我们确定了 10 种 IFIs，这些工具在 2002-15 年间动员了 89 亿美元（占 DAH 的 2.3%）。IFIs 筹集的资金主要通过 GAVI 和全球基金渠道，用于新疫苗和未充分利用的疫苗、艾滋病毒/艾滋病、疟疾、结核病以及母婴健康方案。疫苗接种方案获得的资金最多（26 亿美元），其次是艾滋病毒/艾滋病（1.0807 亿美元）和疟疾（1.028.9 万美元），没有明显针对非传染性疾病的资金。
Zotero 插件